Roche presents new data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022
Updated data from phase-III Polarix study continue to demonstrate a statistically significant reduction in the risk of disease…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Polivy
FDA accepts supplemental Biologics Licence Application for Roche’s Polivy combination
The acceptance has been given for people with previously untreated diffuse large B-cell lymphoma
CHMP recommends EU approval of Roche’s Polivy combination for people with previously untreated…
The recommendation is based on pivotal data from the phase-III Polarix study